{
  "trial_id": "NCT02896855",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, Eastern Cooperative Oncology Group (ECOG) Performance Status, left ventricular ejection fraction (LVEF), prior hormonal therapy for metastatic breast cancer, prior trastuzumab use in the neoadjuvant or adjuvant setting, disease-free interval from completion of systemic treatment to metastatic diagnosis, presence of peripheral neuropathy, history of other malignancies, presence of central nervous system (CNS) metastases, history of congestive heart failure (CHF), history of myocardial infarction, baseline dyspnea status, organ function status, history of major surgical procedures, pregnancy status, infection status (HIV, HCV, HBV), use of intravenous (IV) antibiotics, chronic corticosteroid use, hypersensitivity to study treatments, concurrent study participation.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Disease Type: Visceral or Non-Visceral Disease",
        "Hormone Receptor Status",
        "Measurable or Non-Measurable Disease",
        "According to RECIST v1.1"
      ],
      "remaining_candidate_features": [
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "left ventricular ejection fraction (LVEF)",
        "prior hormonal therapy for metastatic breast cancer",
        "prior trastuzumab use in the neoadjuvant or adjuvant setting",
        "disease-free interval from completion of systemic treatment to metastatic diagnosis",
        "presence of peripheral neuropathy",
        "history of other malignancies",
        "presence of central nervous system (CNS) metastases",
        "history of congestive heart failure (CHF)",
        "history of myocardial infarction",
        "baseline dyspnea status",
        "organ function status",
        "history of major surgical procedures",
        "pregnancy status",
        "infection status (HIV, HCV, HBV)",
        "use of intravenous (IV) antibiotics",
        "chronic corticosteroid use",
        "hypersensitivity to study treatments",
        "concurrent study participation"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, HER2 status, Left Ventricular Ejection Fraction (LVEF), Eastern Cooperative Oncology Group (ECOG) Performance Status, Prior hormonal therapy for metastatic breast cancer, Prior neoadjuvant or adjuvant therapy, Baseline organ function,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Disease Type: Visceral or Non-Visceral Disease",
        "Hormone Receptor Status",
        "Measurable or Non-Measurable Disease",
        "According to RECIST v1.1"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "HER2 status",
        "Left Ventricular Ejection Fraction (LVEF)",
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "Prior hormonal therapy for metastatic breast cancer",
        "Prior neoadjuvant or adjuvant therapy",
        "Baseline organ function"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group Performance Status, Left Ventricular Ejection Fraction, HER2 Status, Menopausal Status, Region of Enrollment, Prior Breast Cancer Therapy, Prior Hormonal Therapy, Prior Trastuzumab Therapy, Prior Anthracycline Therapy, Prior Radiotherapy, Prior Surgery, History of Cardiovascular Disease, History of Hypertension, History of Diabetes Mellitus.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Disease Type: Visceral or Non-Visceral Disease",
        "Hormone Receptor Status",
        "Measurable or Non-Measurable Disease",
        "According to RECIST v1.1"
      ],
      "remaining_candidate_features": [
        "Eastern Cooperative Oncology Group Performance Status",
        "Left Ventricular Ejection Fraction",
        "HER2 Status",
        "Menopausal Status",
        "Region of Enrollment",
        "Prior Breast Cancer Therapy",
        "Prior Hormonal Therapy",
        "Prior Trastuzumab Therapy",
        "Prior Anthracycline Therapy",
        "Prior Radiotherapy",
        "Prior Surgery",
        "History of Cardiovascular Disease",
        "History of Hypertension",
        "History of Diabetes Mellitus"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, left ventricular ejection fraction (LVEF), histological subtype of breast cancer, hormone receptor status, number and location of metastatic sites, prior breast cancer therapy, time since diagnosis of metastatic breast cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Hormone Receptor Status",
          "hormone receptor status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Disease Type: Visceral or Non-Visceral Disease",
        "Measurable or Non-Measurable Disease",
        "According to RECIST v1.1"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "left ventricular ejection fraction (LVEF)",
        "histological subtype of breast cancer",
        "number and location of metastatic sites",
        "prior breast cancer therapy",
        "time since diagnosis of metastatic breast cancer"
      ]
    }
  }
}